This product is a non-steroidal anti-inflammatory drug. It has anti-disease, anti-inflammatory and antipyretic effects in animal models. Its mechanism may be related to the inhibition of prostaglandin synthesis.

This product has a rapid effect and is one of the most potent topical corticosteroids currently used in clinical practice. It has a strong capillary constriction effect, and its anti-inflammatory effect is 112.5 times that of hydrocortisone, 2.3 times that of betamethasone sodium phosphate, and 18.7 times that of fluocinolone. The systemic adverse reactions are 3 times that of fluocinolone, and it has no sodium retention effect, and has a certain effect of promoting sodium and potassium excretion.

It is a 4-nitrogen steroid hormone compound and a specific type II 5α-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone, reduces the level of dihydrotestosterone in the blood and tissues such as the prostate and skin, inhibits prostate hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissues, and improves the related clinical symptoms of benign prostatic hyperplasia.

This drug belongs to the 4-nitrosteroid hormone compound and is a specific type II 5α-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone, reduces the level of dihydrotestosterone in the blood and tissues such as the prostate and skin, and inhibits prostate hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissues, thereby improving the related clinical symptoms of benign prostatic hyperplasia.

Telmisartan is a specific angiotensin II receptor (ATⅠ type) antagonist, which binds to the ATⅠ receptor subtype with high affinity, has no agonist effect, and has selective and long-lasting binding; it has no affinity for other receptors; it does not inhibit human plasma renin, ion channels, and angiotensin converting enzyme II; 80 mg can almost completely inhibit the increase in blood pressure caused by angiotensin II, and the antihypertensive effect lasts for more than 24 hours; it gradually takes effect within 3 hours after the first dose, and the maximum antihypertensive effect is reached in 4 weeks; sudden interruption of treatment will not cause rebound hypertension; the incidence of dry cough is lower than that of angiotensin converting enzyme inhibitors.